Scarica l'app Stockscreener
0.85
6.48%
-0.0589
Dopo l'orario di chiusura:
.84
-0.01
-1.18%
Precedente Chiudi:
$0.9089
Aprire:
$0.89
Volume 24 ore:
105.15K
Relative Volume:
0.37
Capitalizzazione di mercato:
$28.39M
Reddito:
-
Utile/perdita netta:
$-10.21M
Rapporto P/E:
-1.455
EPS:
-0.5842
Flusso di cassa netto:
-
1 W Prestazione:
-3.41%
1M Prestazione:
-8.58%
6M Prestazione:
-18.27%
1 anno Prestazione:
-23.25%
Intervallo 1D:
$0.831
$0.90
Intervallo di 1 settimana:
$0.812
$0.9198
Portata 52W:
$0.6801
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Nome
Neurosense Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Compare NRSN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.85 | 30.35M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie
Panic Selling: Is NeuroSense Therapeutics Ltd still a buy after recent gains2025 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Activity Recap: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowJuly 2025 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
Earnings Miss: What is VCICs valuation compared to sector2025 Momentum Check & Real-Time Price Movement Reports - baoquankhu1.vn
Gap Down: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesTrade Exit Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
What are NeuroSense Therapeutics Ltd. Equity Warrant’s recent SEC filings showingStop Loss & Weekly High Conviction Ideas - mfd.ru
ALS drug PrimeC cuts death risk by 65% - Longevity.Technology
Is NeuroSense Therapeutics Ltd. Equity Warrant stock safe for conservative investorsPortfolio Value Report & Long-Term Safe Investment Ideas - mfd.ru
Aug Chart Watch: Does NeuroSense Therapeutics Ltd Equity Warrant align with a passive investing strategyJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis - MarketBeat
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS - Finviz
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
NeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial - TipRanks
Published on: 2026-02-18 21:38:58 - baoquankhu1.vn
ALS trial: NeuroSense drug extends survival by 14 months, cuts deaths 65% - Stock Titan
Buyout Rumor: Whats the analyst consensus on Invesco Mortgage Capital IncPortfolio Gains Report & Weekly High Return Stock Forecasts - baoquankhu1.vn
How NeuroSense Therapeutics Ltd. stock reacts to global recession fearsJuly 2025 Short Interest & Verified Stock Trade Ideas - mfd.ru
NeuroSense Provides Business Update and Progress for the First Half of 2025 - Intellectia AI
Why is NeuroSense Therapeutics Ltd. stock going downMarket Volume Summary & Daily Risk Controlled Trade Plans - mfd.ru
Why NeuroSense Therapeutics Ltd. Equity Warrant stock could be next big winner2025 EndofYear Setup & Weekly High Return Forecasts - mfd.ru
Is NeuroSense Therapeutics Ltd. stock supported by strong fundamentalsPortfolio Gains Summary & Weekly High Conviction Trade Ideas - mfd.ru
Will NeuroSense Therapeutics Ltd. (H1Z) stock enhance shareholder valueWeekly Investment Report & Pattern Based Trade Signal System - mfd.ru
NeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital Increase - TipRanks
Published on: 2026-02-13 23:05:19 - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. a momentum stock2025 Technical Patterns & Weekly Top Gainers Alerts - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
What are the risks of holding NeuroSense Therapeutics Ltd. Equity Warrant2025 Bull vs Bear & High Accuracy Investment Signals - mfd.ru
Is NeuroSense Therapeutics Ltd. Equity Warrant forming a bullish divergenceWeekly Trade Summary & Weekly Chart Analysis and Guides - mfd.ru
Wall Street Recap: How do insiders feel about Prelude Therapeutics IncorporatedQuarterly Performance Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
MACD Signal: Whats the fair value of NeuroSense Therapeutics Ltd stockAnalyst Upgrade & Weekly Momentum Picks - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. Equity Warrant stock recession proof2025 Performance Recap & High Return Trade Opportunity Guides - mfd.ru
Neurosense Therapeutics stock rises after securing Australian patent for PrimeC - Investing.com Nigeria
NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042 - TipRanks
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition - Nasdaq
Does NeuroSense Therapeutics Ltd. Equity Warrant have strong fundamentalsJuly 2025 Weekly Recap & Consistent Profit Alerts - mfd.ru
How interest rate cuts could boost NeuroSense Therapeutics Ltd. stock2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Fund Flows: Can VTLE disrupt its industryQuarterly Market Review & Weekly Hot Stock Watchlists - baoquankhu1.vn
Market Rankings: Is NeuroSense Therapeutics Ltd Equity Warrant part of any ETFQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Is now the right time to enter Tectonic Therapeutic IncMarket Growth Report & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Buyback Watch: Is HSDT a play on infrastructure spending2025 Volume Leaders & AI Powered Market Trend Analysis - baoquankhu1.vn
Insider Buy: Is SPGPRJ undervalued by DCF analysisJuly 2025 Price Swings & Weekly High Momentum Picks - baoquankhu1.vn
Aug Retail: Will TILE benefit from seasonality2025 Valuation Update & Daily Growth Stock Tips - baoquankhu1.vn
Short Covering: Can SNVPRE expand into new marketsOil Prices & Verified Momentum Stock Watchlist - baoquankhu1.vn
Breakouts Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buying2025 Winners & Losers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Valuation Update: What is DMACs revenue forecastEarnings Overview Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
New Alzheimer’s treatment from NeuroSense gets U.S. patent through 2043 - Stock Titan
Analyst Calls: Is NeuroSense Therapeutics Ltd gaining market sharePortfolio Value Report & Proven Capital Preservation Methods - baoquankhu1.vn
Aug Gainers: Is RCKY stock a value trapJuly 2025 PostEarnings & Reliable Entry Point Alerts - baoquankhu1.vn
Portfolio Shifts: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingJuly 2025 Update & Long-Term Capital Growth Ideas - baoquankhu1.vn
Big Picture: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Weekly Trades: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
Neurosense Therapeutics Ltd Azioni (NRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.90%
2.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):